Eisai cutting 91 jobs after out-license deal; Merck touts first-line Keytruda results in endometrial cancer
Eisai will eliminate 91 after it out-licensed a seizure drug.
An Eisai spokesperson told Endpoints News that the change-up is tied to Fycompa, a seizure …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
